| Bioactivity | Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer[1]. |
| Target | Integrin αV. |
| Invitro | Abituzumab (DI17E6) (0.01, 0.1, 1, 10, 30,100 µg/mL; 24 h) inhibits adhesion of PCa cells to multiple extracellular matrix proteins but not collagen I[1]Abituzumab (100 µg/mL; 12, 18 h) inhibits inhibits motility and invasion of PCa cells[1].Abituzumab (0.01, 0.1, 1, 10, 30,100 µg/mL; 24 h) inhibits the ability of PCa cells to adhere to osteoblast and bone stromal cell lines[1].Abituzumab (100 µg/mL; 24 h) blocks integrin-mediated cell signaling in PCa cancer cell lines[1]. Cell Viability Assay[1] Cell Line: |
| Name | Abituzumab |
| CAS | 1105038-73-0 |
| Appearance | Liquid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jiang Y, et al. Abituzumab Targeting of αV-Class Integrins Inhibits Prostate Cancer Progression. Mol Cancer Res. 2017 Jul;15(7):875-883. |